Anuj Gaggar

COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China

Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

IDDF2020-ABS-0057 Risk of incident hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) virus-infected patients treated with tenofovir disoproxil fumarate (TDF) versus entecavir (ETV): a US administrative claims analysis

Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials

Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment

An OX40/OX40L interaction directs successful immunity to hepatitis B virus

Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma

The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection

Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection

Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA

Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B